A crush of big cap earnings and arguably the most important economic reports until September make next week the busiest of the summer for markets.» Read More
"The recent market collapse has once again rewarded the short sellers," says the head of a website that tracks daily short movements. "Short selling is back."
We ran out of time on TV but just like Melissa Lee promised, our "Final Trades" are here on the website. Our gang gives you tomorrow’s best trades, right now.
If it’s not on your radar it should be, says Guy Adami. What must you know about the Negotiators under the radar stock?
What follows is a look at stocks in the S&P 500 displaying unusual volume in today's trading session.
What follows is a roundup of corporate earnings reports for Monday, May 3.
With the government expected to spend $19 billion upgrading medical records, is Allscripts a can’t lose trade? Hear from the CEO!
It has been over a month and a half since the US House of Representatives passed its version of health care reform and today, the Senate passed its bill. Now the two bills must be reconciled and the debate will continue to heat up. Here are the biggest S&P Health Care gainers and losers over the past 6 months.
With the health care debate continuing, how can investors make money in the sector? Barbara Ryan, managing director and senior pharmaceuticals analyst at Deutsche Bank Securities, and Charles Boorady, health care providers analyst at Citigroup, shared their insights.
This weekend, the US House of Representatives passed its version of health care reform and now awaits a version from the Senate. The debate has been heating up since earlier this summer when President Obama was pushing for legislation before the summer recess. Here are the biggest S&P Health Care gainers and losers over while the debate has waged on.
The Lightning Round is extended in this CNBC.com exclusive feature.
Markets zigzagged on Tuesday as investors juggled a fall in consumer confidence against some positive earnings and housing reports. Erik Ristuben, CIO of Russell Investments, and Joe Ransom, lead portfolio manager at RidgeWorth Select Large Cap Growth Fund, shared their market outlooks.
Worries over health care reform have caused the sector to be underowned, but there are still opportunities for investors looking to take advantage of the low prices, said Charles Boorady of Citigroup and Arthur Henderson of Jeffries & Co.
With $137 billion worth of brand name drugs going generic over the next several years, the recession and the looming threat of healthcare reform a lot of people have been running scared about what it all means for pharma. So, surprise, surprise! This morning IMS Health, which closely monitors the industry, came out with its annual forecast and it now says the American drug market is going to grow this year instead of shrink.
Stocks skidded Tuesday after a report showed consumer confidence is waning amid worries about the job market. It was a struggle all morning as investors juggled another batch of disappointing earnings results against an encouraging report on the housing market.
After a huge two week really, is Tuesday's market weakness an early sign of a sharp pull back or nothing more than expected profit taking?
So far this quarter, only one S&P healthcare company, Aetna, has missed its consensus EPS estimate. This week there are over 20 more healthcare companies reporting. Yesterday after the bell Amgen blew the cover off the ball with a 40% rise in earnings and this morning, Teva Pharmaceuticals beat by three cents per share.
Stock futures drifted slightly lower ahead of the open Tuesday as investors waited for the next batch of earnings and key economic data.
We are at the beginning of a slow and uneven recovery but we will see the S&P 500 reach 1,000 by year-end, said Bob Doll, vice chairman of BlackRock.
Unemployment hit 8.9 percent in April and some predict that number could climb over 10 percent in 2009 as major companies further streamline operations to combat the recession. While some industries are more labor intensive than others, employee productivity is a key measure that managers and investors look at when evaluating performance. Take a look at which companies are squeezing the most out their shrinking workforces.
Although there are some risk factors in the market, David Dietze, president and chief investment strategist at Point View Financial Services, said there are opportunities to “take some chips off the table.”